Screening for adverse reactions to irinotecan treatment using the Invader^®UGT1A1 Molecular Assay

References

• Gong QH, Cho JW, Huang T et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics11, 357–368 (2001).
   PubMedGoogle Scholar
• Bock KW. Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem. Pharmacol.66, 691–396 (2003).
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl. J. Med.333, 1171–1175 (1995).
   PubMed Web of Science ®Google Scholar
• Seppen J, Bosma PJ, Goldhoorn BG et al. Discrimination between Crigler–Najjar Type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J. Clin. Invest.94, 2385–2391 (1994).
   PubMed Web of Science ®Google Scholar
• Ando Y, Chida M, Nakayama K et al. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics8, 357–360 (1998).
   PubMedGoogle Scholar
• Ando Y, Saka H, Ando M et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res.60, 6921–6926 (2000).
   PubMed Web of Science ®Google Scholar
• Ando Y, Ueoka H, Sugiyama T et al. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther. Drug Monit.24, 111–116 (2002).
   PubMed Web of Science ®Google Scholar
• Innocenti F, Grimsley C, Das S et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics12, 725–733 (2002).
   PubMedGoogle Scholar
• Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J.2, 43–47 (2002).
   PubMedGoogle Scholar
• Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol.22, 1382–1388 (2004).
   PubMed Web of Science ®Google Scholar
• Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer91, 678–682 (2004).
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Singh AS, Price DK et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol.44, 854–860 (2004).
   PubMed Web of Science ®Google Scholar
• Kitagawa C, Ando M, Ando Y et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet. Genomics15, 35–41 (2005).
   PubMedGoogle Scholar
• Ando Y, Hasegawa Y. Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab. Rev.37, 565–574 (2005).
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med.346, 85–91 (2002).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343, 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Tadokoro J, Hasegawa H, Hayakawa K et al. Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients. Proc. Am. Soc. Clin. Oncol.21(Suppl.), 259a (2002) (Abstract 1033).
   Google Scholar
• Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest.101, 847–854 (1998).
   PubMed Web of Science ®Google Scholar
• Iyer L, Hall D, Das S et al. Phenotype–genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther.65, 576–582 (1999).
   PubMed Web of Science ®Google Scholar
• Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J.303(Pt 1), 233–240 (1994).
   PubMed Web of Science ®Google Scholar
• Ritter JK, Chen F, Sheen YY et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem.267, 3257–3261 (1992).
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Owens IS, Burchell B et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics7, 255–269 (1997).
   PubMedGoogle Scholar
• Monaghan G, Ryan M, Seddon R et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert’s syndrome. Lancet347, 578–581 (1996).
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Soeda Y, Kamisako T et al. Analysis of bilirubin uridine 5´-diphosphate (UDP)-glucuronosyltransferase gene mutations in seven patients with Crigler–Najjar syndrome Type II. J. Hum. Genet.43, 111–114 (1998).
   PubMed Web of Science ®Google Scholar
• McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J. Clin. Oncol.22, 1356–1359 (2004).
   PubMed Web of Science ®Google Scholar
• Akaba K, Kimura T, Sasaki A et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int.46, 21–26 (1998).
   PubMedGoogle Scholar
• Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA95, 8170–8174 (1998).
   PubMed Web of Science ®Google Scholar
• Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther.75, 501–515 (2004).
   PubMed Web of Science ®Google Scholar
• Akaba K, Kimura T, Sasaki A et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J. Hum. Genet.44, 22–25 (1999).
   PubMed Web of Science ®Google Scholar
• Maruo Y, Nishizawa K, Sato H et al. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics103, 1224–1227 (1999).
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Sato H, Fujiyama Y et al. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert’s syndrome and Crigler–Najjar syndrome Type II. Biochim. Biophys. Acta1406, 267–273 (1998).
   PubMed Web of Science ®Google Scholar
• Sato H, Adachi Y, Koiwai O. The genetic basis of Gilbert’s syndrome. Lancet347, 557–558 (1996).
   PubMed Web of Science ®Google Scholar
• Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol.24, 2237–2244 (2006).
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Sarashina T, Ando M et al. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem.50, 1479–1480 (2004).
   PubMed Web of Science ®Google Scholar
• Lyamichev V, Mast AL, Hall JG et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat. Biotechnol.17, 292–296 (1999).
   PubMed Web of Science ®Google Scholar
• Ghosh SS, Eis PS, Blumeyer K et al. Real time kinetics of restriction endonuclease cleavage monitored by fluorescence resonance energy transfer. Nucleic Acids Res.22, 3155–3159 (1994).
   Google Scholar
• Patnaik M, Dlott JS, Fontaine RN et al. Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay. J. Mol. Diagn.6, 137–144 (2004).
   PubMed Web of Science ®Google Scholar
• Neville M, Selzer R, Aisenstein B et al. Characterization of cytochrome P450 2D6 alleles using the Invader System. Biotechniques32, S34–S43 (2002).
   PubMedGoogle Scholar
• Kitagawa C, Ando M, Ando Y et al. Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and irinotecan toxicity. Proc. Am. Soc. Clin. Oncol.22(Suppl.), 129 (2004) (Abstract 2009).
   Google Scholar
• Innocenti F, Undevia SD, Chen PX et al. Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: evidence for a functional variant of ABCC2. Proc. Am. Soc. Clin. Oncol.22(Suppl.), 129 (2004) (Abstract 2010).
   Google Scholar